Use of B-type natriuretic peptide as a prognostic indicator in acute coronary syndromes
AssigneeBiosite, Inc.
InventorsJeffrey R. Dahlen, Kenneth F. Buechler, Gunars E. Valkirs
Life of this patent
Estimating the term…
Abstract
The present invention relates to materials and procedures for evaluating the prognosis of patients suffering from acute coronary syndromes. In particular, the level of BNP, or a marker related to BNP, in a patient sample, alone or in combination with one or more other prognostic markers, provides prognostic information useful for predicting near-term morbidity and/or mortality across the entire spectrum of acute coronary syndromes, including unstable angina, non-ST-elevation non-Q wave myocardial infarction, ST-elevation non-Q wave MI, and transmural (Q-wave) MI.
Claims18
A method of determining a prognosis of a patient diagnosed with a non-ST-elevation acute coronary syndrome, the method comprising:
- determining a level of a polypeptide originating from pre-pro B-type natriuretic peptide in a sample obtained from said patient;
- and
- correlating said polypeptide level to said patient prognosis by determining if said polypeptide level is associated with a predisposition to an adverse outcome of said non-ST-elevation acute coronary syndrome.
Dependencies are inferred from the claim text.